Literature DB >> 6360247

Diagnosis and classification of severe combined immunodeficiency disease.

E W Gelfand, H M Dosch.   

Abstract

The failure to demonstrate normal humoral and cell-mediated immunity (CMI) in patients diagnosed as SCID is seen to reflect the varied pathogenesis of this syndrome. Two major groups of patients have been described, those with or without an associated absence of the enzyme ADA. The heterogeneity of the syndrome is expressed in variable inheritance patterns (particularly defined X-linked or autosomal recessive modes of inheritance), differing clinical presentations, and significant variability in laboratory findings. Some of this heterogeneity of laboratory findings may in fact be contributed to by the high incidence of infection or engraftment of maternal cells in utero. Common to all, however, is the profound deficiency of functional attributes of humoral and cell-mediated immunity. Insight into the biology of this immunodeficiency has advanced steadily in the last decade. Although initially hypothesized to represent a primary lymphoid stem-cell defect, newer technologies to identify and enumerate lymphocyte subpopulations and precursor lymphocytes have revealed the complexity of the disorder. This complexity may now be attributable to a number of abnormalities in the quantitative and qualitative differentiation of these lymphoid stem cells. Functional differentiation of lymphocytes is the result of a progressive and orderly sequence of events. In SCID, lymphocytes of both lineages may be arrested at specific and identifiable stages of maturation, leading to a deficiency of cell-mediated and humoral immunity. In many patients with SCID, the combined immune deficiency may be linked solely to a failure in the stepwise progression of T-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360247

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  13 in total

Review 1.  Genetics of human X-linked immunodeficiency diseases.

Authors:  R W Hendriks; R K Schuurman
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

2.  Nonrandom X chromosome inactivation in B cells from carriers of X chromosome-linked severe combined immunodeficiency.

Authors:  M E Conley; A Lavoie; C Briggs; P Brown; C Guerra; J M Puck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

3.  Carrier detection in X-linked severe combined immunodeficiency based on patterns of X chromosome inactivation.

Authors:  J M Puck; R L Nussbaum; M E Conley
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  A novel X-linked combined immunodeficiency disease.

Authors:  E G Brooks; F C Schmalstieg; D P Wirt; H M Rosenblatt; L T Adkins; D P Lookingbill; H E Rudloff; T A Rakusan; A S Goldman
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  A variable immunoreceptor in a subpopulation of human neutrophils.

Authors:  Kerstin Puellmann; Wolfgang E Kaminski; Mandy Vogel; C Thomas Nebe; Josef Schroeder; Hans Wolf; Alexander W Beham
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

6.  Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations.

Authors:  H Ratech; R Hirschhorn; M A Greco
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

7.  Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donors.

Authors:  W Friedrich; S F Goldmann; W Ebell; R Blütters-Sawatzki; G Gaedicke; A Raghavachar; H H Peter; B Belohradsky; W Kreth; B Kubanek
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

8.  X-linked severe combined immunodeficiency. Diagnosis in males with sporadic severe combined immunodeficiency and clarification of clinical findings.

Authors:  M E Conley; R H Buckley; R Hong; C Guerra-Hanson; C M Roifman; J A Brochstein; S Pahwa; J M Puck
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

9.  T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.

Authors:  K Weinberg; M S Hershfield; J Bastian; D Kohn; L Sender; R Parkman; C Lenarsky
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Acute monocytic leukemia in a dog with X-linked severe combined immunodeficiency.

Authors:  P J Felsburg; R L Somberg; G S Krakowka
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.